| |
| |
|
| Insider
Information: |
Baker Bros. Advisors (gp) Llc |
| Relationship: |
|
| City: |
New York |
| State: |
NY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
16 |
|
| Direct
Shares |
608,718 |
|
|
Indirect Shares
|
158,658,441 |
|
|
| Direct
Value |
$42,508,355 |
|
|
|
Indirect Value
|
$12,755,792,609 |
|
|
| Total
Shares |
159,267,159 |
|
|
| Total
Value |
$12,798,300,963 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
1
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -74.7%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Genomic Health Inc |
GHDX |
Director, 10% Owner |
2013-07-01 |
0 |
2019-02-27 |
9,235,362 |
Premium* |
|
|
Acadia Pharmaceuticals Inc |
ACAD |
Director, 10% Owner |
2014-03-05 |
0 |
2016-04-01 |
41,897,946 |
Premium* |
|
|
Incyte Corp |
INCY |
Director, 10% Owner |
2021-05-14 |
559,963 |
2021-05-14 |
29,367,926 |
Premium* |
|
|
XOMA Corporation |
XOMA |
Director, 10% Owner |
2014-05-22 |
0 |
2014-05-22 |
518,849 |
Premium* |
|
|
Aceragen, Inc |
ACGN |
Director |
2014-07-01 |
0 |
2016-01-04 |
78,885 |
Premium* |
|
|
Synageva BioPharma Corp |
GEVA |
Director, 10% Owner |
2015-01-07 |
1,020 |
2015-01-07 |
11,877,394 |
Premium* |
|
|
Mirati Therapeutics, Inc. |
MRTX |
10% Owner |
2016-06-09 |
274 |
2016-06-09 |
30,003 |
Premium* |
|
|
Intellia Therapeutics, Inc. |
NTLA |
Former 10% owner |
2016-05-11 |
0 |
2016-05-11 |
976,214 |
Premium* |
|
|
Invitae Corp |
NVTA |
10% Owner |
2016-11-17 |
0 |
2016-11-17 |
6,554,039 |
Premium* |
|
|
Bellicum Pharmaceuticals, Inc |
BLCM |
10% Owner |
2017-03-24 |
0 |
2023-11-22 |
2,168,818 |
Premium* |
|
|
Seagen Inc |
SGEN |
Director, 10% Owner |
2023-05-31 |
46,557 |
2023-05-31 |
42,977,301 |
Premium* |
|
|
Neurogene |
NGNE |
Director, 10% Owner |
2023-10-05 |
904 |
2023-10-05 |
1,658,190 |
Premium* |
|
|
Entrada Therapeutics, Inc. |
TRDA |
10% Owner |
2022-05-16 |
0 |
2022-06-06 |
4,501,658 |
Premium* |
|
|
Atreca Inc |
BCEL |
Former 10% Owner |
2023-10-19 |
0 |
2023-10-19 |
2,971,128 |
Premium* |
|
|
Igm Biosciences, Inc. |
IGMS |
|
2023-12-13 |
0 |
2024-03-29 |
3,755,474 |
Premium* |
|
|
Vtv Therapeutics Inc. |
VTVT |
|
2024-03-05 |
0 |
2024-03-05 |
89,254 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
103 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 5
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| BLCM |
Bellicum Pharmaceuticals,... |
10% Owner |
– – • |
2023-05-05 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
249,123 |
|
% |
|
| VTVT |
Vtv Therapeutics Inc. |
|
– • – |
2024-02-27 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
154,971 |
|
- |
|
| XOMA |
XOMA Corporation |
Director |
– • • |
2014-05-22 |
4 |
A |
$0.00 |
$0 |
I/I |
25,200 |
518,849 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • • |
2015-09-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,698 |
61,049 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • • |
2015-09-16 |
4 |
OE |
$0.00 |
$0 |
I/I |
4,609,228 |
512,673 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
Former 10% owner |
– – – |
2016-05-11 |
4 |
A |
$0.00 |
$0 |
I/I |
862,120 |
796,683 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • • |
2017-02-17 |
4 |
A |
$0.00 |
$0 |
I/I |
10,610,782 |
767,095 |
0 |
- |
|
| SGEN |
Seagen Inc |
Director |
– • • |
2019-06-06 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,002,483) |
4,302,354 |
0 |
- |
|
| SGEN |
Seagen Inc |
Director |
– • • |
2019-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
148,458 |
181,733 |
0 |
- |
|
| NGNE |
Neurogene |
Director |
– • – |
2019-12-20 |
4 |
D |
$0.00 |
$0 |
I/I |
(10,925,481) |
3,107,331 |
0 |
- |
|
| SGEN |
Seagen Inc |
Director |
– • • |
2022-05-13 |
4 |
A |
$0.00 |
$0 |
I/I |
3,006 |
42,966,507 |
0 |
- |
|
| SGEN |
Seagen Inc |
Director |
– • • |
2023-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
418,350 |
232,452 |
0 |
- |
|
| SGEN |
Seagen Inc |
Director |
– • • |
2023-05-01 |
4 |
D |
$0.00 |
$0 |
I/I |
(2,368,357) |
1,729,158 |
0 |
- |
|
| SGEN |
Seagen Inc |
Director |
– • • |
2023-05-02 |
4 |
GD |
$0.00 |
$0 |
D/D |
418,350 |
23,277 |
0 |
- |
|
| SGEN |
Seagen Inc |
Director |
– • • |
2023-05-31 |
4 |
A |
$0.00 |
$0 |
I/I |
4,088 |
42,977,301 |
0 |
- |
|
| NGNE |
Neurogene |
Director |
– • • |
2023-10-05 |
4 |
OE |
$0.00 |
$0 |
I/I |
592,650 |
1,658,190 |
0 |
- |
|
| IGMS |
Igm Biosciences, Inc. |
|
– • • |
2023-12-29 |
4 |
A |
$0.00 |
$0 |
I/I |
1,108 |
3,390,877 |
0 |
- |
|
| VTVT |
Vtv Therapeutics Inc. |
|
– • – |
2024-03-05 |
4 |
D |
$0.00 |
$0 |
I/I |
(57,657) |
89,254 |
0 |
- |
|
| IGMS |
Igm Biosciences, Inc. |
|
– • • |
2024-03-29 |
4 |
A |
$0.00 |
$0 |
I/I |
3,988 |
3,755,474 |
0 |
- |
|
| BLCM |
Bellicum Pharmaceuticals,... |
10% Owner |
– – • |
2023-11-22 |
4 |
OE |
$0.00 |
$212 |
I/I |
2,116,349 |
2,168,818 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
10% Owner |
– – • |
2016-03-30 |
4 |
OE |
$6.74 |
$1,847 |
D/D |
274 |
137 |
0 |
- |
|
| TRDA |
Entrada Therapeutics, Inc... |
10% Owner |
– – • |
2022-06-02 |
4 |
B |
$5.82 |
$15,383 |
I/I |
2,643 |
4,467,393 |
1.5 |
- |
|
| TRDA |
Entrada Therapeutics, Inc... |
10% Owner |
– – • |
2022-05-23 |
4 |
B |
$5.99 |
$46,923 |
I/I |
7,837 |
4,443,719 |
1.5 |
- |
|
| ACGN |
Aceragen, Inc |
Director |
– • – |
2014-07-01 |
4 |
A |
$2.83 |
$52,485 |
I/I |
18,546 |
41,287 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • • |
2016-09-30 |
4 |
A |
$94.29 |
$56,857 |
I/I |
603 |
533,720 |
0 |
- |
|
103 Records found
|
|
Page 1 of 5 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
